Introduction
============

*Enterococcus* has become one of the most important opportunistic pathogens leading to nosocomial infections, posing significant challenge to clinicians. The vast majority of clinical enterococcal infections in humans are caused by *Enterococcus faecalis* and *E. faecium. E. faecium*, much less frequently isolated than *E. faecalis*, has a higher incidence of resistance to multiple antimicrobial agents.[@b1-idr-11-2397] According to the Zyvox Annual Appraisal of Potency and Spectrum (ZAAPS) program data, ampicillin, erythromycin, levofloxacin, and teicoplanin resistance rates for *E. faecalis* and *E. faecium* were 0% and 91.8%, 53.7% and 88.4%, 25.4% and 90.8%, and 0.4% and 14.7%, respectively.[@b2-idr-11-2397] In 2016, the European Union and European Economic Area population-weighted mean percentage for high-level gentamicin resistance in *E. faecalis* was 30.5%, with national percentages ranging from 12.5% to 56.3%.[@b3-idr-11-2397] It is of note that the number of vancomycin-resistant *Enterococcus* (VRE) has been increasing, resulting in the limited selection for treatment. Vega and Dowzicky showed that 40.8% (235/576) *E. faecium* and 1.6% (33/2,004) *E. faecalis* isolates were vancomycin-resistant.[@b4-idr-11-2397]

Linezolid was approved for management of VRE infections by the American Food and Drug Administration in 2000. Then linezolid-resistant *Enterococcus* was reported 1 year later. According to the ZAAPS and Linezolid Experience and Accurate Determination of Resistance program, the proportion of linezolid resistance in *Enterococcus* was 0.22% (21/9,417) and 0.78% (67/8,604), respectively. The main resistance mechanisms included alterations in the ribosomal proteins L3 and/or L4, mutations in domain V of the 23S rRNA, and/or presence of *cfr* or *optrA* gene. Resistance to linezolid in VRE is a result of decreased binding due to mutations at the 23S rRNA or acquisition of a *cfr* gene through horizontal transmission.[@b5-idr-11-2397],[@b6-idr-11-2397]

The treatment and clinical outcomes regarding linezolid-resistant *Enterococcus* were limited. Older age, male gender, renal impairment, liver disease, diabetes, solid organ, and hematologic transplant have all been identified as risk factors for enterococcal blood stream infections in nonselected observational cohort studies. In addition, Billington et al[@b7-idr-11-2397] found that *E. faecalis* infections were associated with a urinary focus, genitourinary malignancy, and abnormal genitourinary anatomy. However, risk factors for linezolid resistance reported in the literature have been inconsistent.[@b8-idr-11-2397] The aim of this study was to evaluate the epidemiological, virulence factors, antibiotic resistance mechanism, and clinical profiles of LZR-Efa infections, gaining insights into control and prevention of resistance transmission.

Methods
=======

Bacterial strains and clinical data
-----------------------------------

A total of 730 *E. faecalis* isolates were collected from patients hospitalized at The First Affiliated Hospital of Zhejiang University from January 2011 to December 2015. Species identification was conducted by API20 (bioMérieux, Durham, NC, USA) and MALDI-TOF technique (Bruker Diagnostics, Bremen, Germany). Linezolid susceptibility was screened via agar dilution method to determine minimal inhibitory concentration (MIC). The isolates with MIC of linezolid ≥8 mg/L were frozen at −80°C for further analysis.

The LZR-Efa infection group was compared with the linezolid-sensitive *E. faecalis* (LZS-Efa) infection group to evaluate the risk factors for linezolid resistance. The two groups were matched for age, same sex, specimen sources, and department (ratio: 1:2) from the same collection year. The medical records of patients were reviewed by two researchers. The included data were as follows: demographics, clinical characteristics (underlying diseases, comorbidities, invasive procedures, surgical procedures), laboratory examination, treatment history, hospitalization, and clinical outcomes. Antimicrobial drug exposure referred to the use of antibiotics for more than 72 hours at any point 2 weeks prior to diagnosis.

The work was in accordance with the Declaration of Helsinki. This study was approved by the recommendations of the Ethics Committee of the First Affiliated Hospital, College of Medicine, Zhejiang University, with reference number 2018502. To protect personal privacy, identifying information of each patient in the electronic database was encrypted. Informed consent was waived by the Clinical Research Ethics Committee because no intervention was involved and no patient-identifying information was included.

Antibiotic susceptibility test
------------------------------

Antibiotic agents (oxacillin, cefazolin, cefuroxime, clindamycin, erythromycin, levofloxacin, moxifloxacin, tetracycline, tigecycline, amikacin, fosfomycin, trimethoprim-sulfamethoxazole, linezolid, vancomycin, daptomycin, rifampin) were purchased from Dalian Meilun Biotech (Dalian, China). Glucose-6-phosphate was obtained from Sigma-Aldrich Co. (St Louis, MO, USA). Tigecycline and daptomycin susceptibility test were done via broth dilution method according to CLSI recommendations. The MICs of the other 15 antibiotics were determined using the twofold serial agar dilution method.[@b9-idr-11-2397] *E. faecalis* ATCC 29212 were used as quality-control strains.

Multilocus sequence typing (MLST)
---------------------------------

MLST was performed on all LZR-Efa isolates using the scheme of Institute Pasteur, and the sequence types (STs) were assigned using the MLST database (<http://pubmlst.org/ecloacae>). A minimal spanning tree was generated by using BioNumerics v7.0 to provide a graphical representation of the clonal distribution of LZR-Efa.

Whole-genome sequencing (WGS) and data analysis
-----------------------------------------------

WGS was carried out for 26 LZR-Efa with further analysis of gene environment. Genomic DNA was extracted by QIAamp DNA Mini Kit (Qiagen, Hilden, Germany) and sequenced using HiSeq 2000 (Illumina, San Diego, CA, USA) with constructing 2×125 bp paired-end libraries. De novo assembly was done using the CLC Workbench v8.0 (QIAGEN, Hilden, Germany). The resistance genes were identified by BLAST against the ResFinder 2.1 database (<https://cge.cbs.dtu.dk/services/ResFinder/>). The bioinformatics tools used in this study were available at the following web platforms: National Center for Biotechnological Information, Sequence Manipulation Suite, and European Bioinformatics Institute.

This Whole Genome Shotgun BioProject for LZR-Efa has been deposited at GenBank under the accession QNGG00000000--QNHF00000000 ([Table S1](#SD1-idr-11-2397){ref-type="supplementary-material"}).

Statistical analysis
--------------------

Continuous variables were presented as mean ± SD (x±SD), and independent samples *t*-tests were used for comparisons. Data with non-normal distribution were expressed as medians with corresponding IQRs and compared using the Wilcoxon rank-sum test. Categorical variables presented as numbers and percentages and compared percentages using the chi-squared test. For multivariate analysis, binary logistic regression was used to identify risk factors. A two-tailed *P*-values \<0.05 were considered to be statistically significant. Data analysis was performed using SPSS Statistics for Windows, version 17.0 (SPSS Inc., Chicago, IL, USA).

Results
=======

Detection of linezolid-resistant clinical isolates and their clinical characteristics
-------------------------------------------------------------------------------------

Among 730 clinical *E. faecalis* isolates over the study period, 26 (3.5%, 26/730) were resistant to linezolid. The incidences of LZR-Efa were 0%--1.2%, 4.4%--5.07%, and 2.5% from 2011 to 2015. The patients ranged in age from 18 to 70 years ([Table 1](#t1-idr-11-2397){ref-type="table"}). There were 11 males and 15 females, 4 of whom were outpatients. These samples obtained from culture included urine (n=13), ascites (n=5), bile (n=3), fester (n=3), and blood (n=2). The patients were from multiple cities in the Zhejiang Province, China. Medical records were reviewed, and patient histories confirmed that they had not been prescribed linezolid or traveled abroad previously. With the exception of one patient who died of multiple organ dysfunction syndrome, all the other patients recovered.

Characteristics of the antibiotic susceptibility and sequence types (STs)
-------------------------------------------------------------------------

The susceptibility test results for the 26 strains are shown in [Table 2](#t2-idr-11-2397){ref-type="table"}. All isolates were resistant to cefazolin, cefuroxime, clindamycin, and amikacin, whereas 46.1% (12/26), 69.2% (18/26), 69.2% (18/26), 73.1% (19/26), 84.6% (22/26), 88.5% (23/26), and 92.3% (24/26) of strains were resistant to oxacillin, trimethoprim-sulfamethoxazole, moxifloxacin, levofloxacin, tetracycline, erythromycin, and tigecycline, respectively. Rifampin resistance was seen in 30.8% (8/26) of the isolates. Only one strain showed intermediate sensitivity to fosfomycin. However, 15.4% (4/26) isolates were daptomycin nonsusceptible. In total, all these linezolid-resistant isolates retained susceptibility to vancomycin. Besides 12,654 and 24,393, other isolates were multidrug-resistant LZR-Efa.

A total of 13 different STs were identified from 26 LZR-Efa isolates. The most prevalent type was ST16 (six isolates, 23.1%), followed by ST585 (five isolates, 19.2%), ST476 (three isolates, 11.5%), and ST480 (three isolates, 11.5%). Three new STs were identified (ST856--ST858) ([Figure 1](#f1-idr-11-2397){ref-type="fig"}).

Antibiotic resistance mechanism of LZREfa
-----------------------------------------

In an attempt to link the phenotypic resistance data with genotypic evidence of resistance, we searched for mutations known to confer antimicrobial resistance. The genes *dfrE*, *lsaA*, and *emeA* were identified in all isolates ([Table S2](#SD2-idr-11-2397){ref-type="supplementary-material"}). Among the 26 LZR-Efa isolates examined in this study, 23 *E. faecalis* were positive for *optrA* gene. Six amino acids mutations were identified among the 18 LZR-Efa isolates, and of which Pro463Thr (463 tryptophan acid was changed to be threonine) was most frequently detected in isolates ([Table 2](#t2-idr-11-2397){ref-type="table"}). Both Pro463Thr and Asp158Tyr mutations of OptrA were the most abundant in LZR-Efa (12/18). Besides other two sites, Pro463Thr and Ile604Met mutations in three ST585 isolates, three mutational loci (Pro463Thr, Glu238Lys, and Ile86Arg) were found in two ST16 isolates. In addition, the 23S rRNA mutation was found in 16 LZR-Efa isolates ([Table 2](#t2-idr-11-2397){ref-type="table"}). It is of note that 10 isolates had both OptrA and 23S rRNA mutations. Mutations of specific amino acids were found in same type ST or ST with one allele difference. However, the presence of plasmid-borne ribosomal methyltransferase gene, *cfr*, was not identified in 26 LZR-Efa.

Characteristics of virulence genes
----------------------------------

There were 41 virulence genes detected and 10 genes (*ace*, *bopD*, *cpsA*, *cpsB*, *ebpB*, *ebpC*, *efaA*, *fss1*, *fss2*, and *srtC*) were found in all isolates ([Table S3](#SD3-idr-11-2397){ref-type="supplementary-material"}). Of all the LZR-Efa isolates, 96.2% (25/26) were positive for *ebpA*, 88.5% (23/26) were positive for *EF3023*, 69.2% (18/26) were positive for nine genes (*asa1*, *cpsC*, *cpsD*, *cpsE*, *cpsG*, *cpsH*, *cpsI*, *cpsJ*, and *cpsK*), 69.2% (18/26) were positive for five genes (*esp*, *fsrB*, *fsrC*, *gelE*, and *prgB/asc10*), and 69.2% (18/26) were positive for three genes (*cpsF*, *fsrA*, and *sprE*). The *hyl* and *agg* genes were not detected in any LZR-Efa isolates. The *bsh* gene was found in 15,224 isolated from bile. A total of nine isolates were positive for multiple virulent factors (*ace*, *asa1*, *cylA*, *efaA*, *esp*, and *gelE*). There was no relationship between the number of virulence factors and clinical specimens (*P*=0.825).

Risk factors associated with the development of LZR-Efa
-------------------------------------------------------

There were a total of 20 patients with LZR-Efa infections, and 40 patients with LZS-Efa were enrolled by reference to the matching criteria in the Methods section. Compared with patients with LZS-Efa, univariate analysis showed that those with LZR-Efa were more likely to exposure to carbapenem (*P*=0.007) ([Table 3](#t3-idr-11-2397){ref-type="table"}). The logistic regression analysis indicated that the previous use of carbapenems may be an independent risk factor for LZR-Efa infection (OR=6.631; 95% CI=1.489--29.522; *P*=0.013).

Discussion
==========

Since linezolid launched on the market, the detection rate of LZR-Efa and even the incidence of MDR are increasing.[@b8-idr-11-2397] Although the prevalence of linezolid resistance is still low, emergence and dissemination of linezolid-resistant *enterococci* limit the therapeutic option for successful treatment of VRE infections. In the present study, with the analysis of LZR-Efa, we found MDR LZR-Efa were not spread by clonal strains. In addition, *optrA* and 23S rRNA were the main resistance mechanisms. Notably, all linezolid-resistant vancomycin-susceptible *E. faecalis* emerged without linezolid treatment. The virulence factors, associated with bacterial adherence, evasion of phagocytosis, and biofilm formation, were identified, while the stress response proteins were not found in any isolates. Furthermore, data from 60 patients were evaluated, and the results showed previous carbapenems exposure to be an independent risk factor for LZR-Efa infections.

The majority of LZR-Efa in our study was from urinary source, in keeping with prior observations.[@b7-idr-11-2397] With an intrinsic and acquired resistance to some antimicrobial agents, *enterococci* have become important nosocomial pathogens.[@b10-idr-11-2397] Although the prevalence of linezolid-resistant enterococci is currently very low, the incidence of LZR-Efa in the hospital setting, which was 3.6% (26/730) in this study, was higher than that in Europe.[@b3-idr-11-2397] Of concern, 15.4% (4/26) isolates were daptomycin nonsusceptible. Note that, 1.8% (7/389) vancomycin-resistant *E. faecium* isolates were found to be resistant to linezolid in South Korea, which severely restricted the treatment options.[@b11-idr-11-2397] Fortunately, all LZR-Efa isolates in our study were susceptible to vancomycin without creating a worse crisis in clinical treatment.

Overall, the clones of 26 LZR-Efa isolated in different time periods were diverse. The dominance of ST16 among our samples is somewhat consistent with prior studies in Malaysia and China.[@b12-idr-11-2397] The same types of *E. faecalis*, ST16, ST27, ST116, ST256, ST476, ST480, and ST593, were detected in samples from animals and meat as well.[@b13-idr-11-2397],[@b14-idr-11-2397] The data presented here indicated that animal origin seemed to constitute a reservoir of LZR-Efa. Further investigations are needed to assess whether these LZR-Efa was indeed associated with the isolates from animals.

In the present study, *optrA* and 23S rRNA were the main resistance mechanisms for linezolid. The gene *optrA* could be horizontally transmitted among *enterococci*.[@b5-idr-11-2397] In parallel, these surveillance data suggest that *optrA* may be disseminating in *E. faecalis* more rapidly than *cfr* in *Staphylococcus aureus*, implying a greater transferability of *optrA*.[@b15-idr-11-2397] In addition, the *optrA*-positive incidence increased over time from 0.4% (1/262) in 2004--2005 to 3.9% (26/668) in 2013--2014.[@b16-idr-11-2397] Previous studies found that *optrA* gene was more frequently seen in *E. faecalis* than in *E. faecium* and in food-producing animals than in humans (15.9% and 2%--2.9%, respectively).[@b14-idr-11-2397],[@b17-idr-11-2397] Interestingly, the *optrA* gene was detected in an *E. faecium* isolate 2 years before linezolid approval applications in China.[@b16-idr-11-2397] Therefore, the species and geographies cross transmission might be one of the major reasons.

In general, the 23S rRNA mutation was considered as the most common mechanism of linezolid resistance. The 23S rRNA mutation rate of LZR-Efa was 61.5% (16/26), which is consistent with previous study.[@b5-idr-11-2397] It has been demonstrated that 23S rRNA mutations could revert to a susceptible phenotype when selective drug pressure was removed, while rapid resistance selection emerged when selective pressure returned.[@b18-idr-11-2397] Meanwhile, Alonso et al[@b19-idr-11-2397] validated that the isolates with high linezolid MIC value were strongly related to the high number of 23S rRNA mutation copies. However, all LZR-Efa with 23S rRNA mutations showed low-level resistance in our study. And no isolates carried *cfr* gene in LZR-Efa. Although linezolid nonsusceptible clinical isolates almost exclusively harbored 23S rRNA alterations in the early 2000s, the detection rates of *optrA* and *cfr* were increasing in recent years. Therefore, the changes associated with linezolid resistance mechanisms are worthy of great concern.

Previous studies have demonstrated that some virulence factors play important roles in the pathogenesis of *E. faecalis*. Our present study found 10 virulence genes (*ace*, *bopD*, *cpsA*, *cpsB*, *ebpB*, *ebpC*, *efaA*, *fss1*, *fss2*, and *srtC*) in all isolates, and 9 isolates were positive for multiple virulent factors (*ace*, *asa1*, *cylA*, *efaA*, *esp*, and *gelE*). These virulence factors were mainly associated with bacterial adherence, evasion of phagocytosis, and biofilm formation. Several proteins, such as CYL and GelE, secreted into the extracellular medium have been implicated in enterococcal virulence. Meanwhile, cell-surface determinants, including the family of aggregation substance proteins (AS proteins), pilin, polysaccharides, polysaccharide antigen, have been reported to contribute to the large bacterial aggregations and biofilm formation. Esp, as one of AS proteins, are anchored to the cell wall, affect biofilm formation, and have a role in experimental urinary tract infections (UTIs) and/or endocarditis model.[@b20-idr-11-2397],[@b21-idr-11-2397] Capsular polysaccharide (cps) has a crucial role in pathogenesis, mediating evasion of phagocytosis by polymorphonuclear neutrophils, and stimulating cytokine production.[@b22-idr-11-2397] Ebp pili are important for biofilm formation and for the pathogenesis of experimental endocarditis and UTIs.[@b23-idr-11-2397] Zheng et al[@b12-idr-11-2397] demonstrated a positive association between linezolid resistance in *E. faecalis* and robust biofilm formation. They found that the *cylA* gene was associated with weak biofilm formation, while the *esp* gene was only associated with strong or medium biofilm formation. It is of note that some stress response proteins (Gls, Npr, Ahp, Tpx), being important for virulence, were not identified in this present study. In addition, various putative enterococcal virulence determinants can also be found in strains colonizing the gastrointestinal tract of healthy individuals.[@b24-idr-11-2397] The evidence of involvement of pathogenic factors still needs to be confirmed by further studies.

Usually, the emergence of linezolid-resistant enterococci was consistently related to prior linezolid exposure.[@b8-idr-11-2397] Of the 55 studies on LZR-Efa, 14 (25.5%) reported the duration of linezolid treatment, with a mean of 29.8±48.8 days.[@b5-idr-11-2397] Paradoxically, LZR-Efa could also develop in patients without prior exposure to linezolid in our study and previous studies. The similar studies suggested the presence of risk factors that predispose the linezolid resistance of the vancomycin-susceptible *Enterococcus*, such as exposure to other antibiotics, long-term hospitalization, and prolonged stay in the intensive care unit.[@b5-idr-11-2397],[@b25-idr-11-2397] Notably, we identified previous use of carbapenems as the only independent risk factor associated with LZR-Efa infections. After applying a logistic regression model, an independent risk factor for *E. faecium* acquisition was the previous use of carbapenems (OR=10.24; 95% CI=1.35--77.66).[@b26-idr-11-2397] Other reports showed that the use of carbapenems is an independent predictor of *E. faecium* bacteremia.[@b27-idr-11-2397] Empirical treatment with broad spectrum antibiotic may facilitate colonization and infection by depleting the gastrointestinal tract of its normal anaerobic flora. Therefore, we speculate that the acquisition of linezolid resistance among *E. faecalis* clinical isolates in the present study was not associated with the consumption of linezolid. It is possible that LZR-Efa colonization without symptoms in the intestinal tract served as a reservoir to be transmitted to other patients or changed into pathogenic bacteria.

The study has several limitations, including its retrospective form and the relatively small number of LZR-Efa. However, this is a real-life clinical experience providing useful suggestions to clinicians about the clinical characteristics of infections caused by LZR-Efa.

Conclusion
==========

The results of our study showed that LZR-Efa were sporadic with low-level linezolid resistance, while multidrug resistance was quite serious. In addition, carbapenems use was an independent predictor of LZR-Efa infections. Therefore, it is important to implement infection-control practices against these resistant strains, with an emphasis on contact precautions and more careful use of antibiotics to prevent selection of resistance.

Supplementary materials
=======================

###### 

Essential information of whole-genome sequencing for 26 LZR-Efa

  Isolates   Accession      Clean reads   Clean bases     Length   Q30%    GC%
  ---------- -------------- ------------- --------------- -------- ------- -------
  6,888      QNGG00000000   8,086,306     1,212,945,900   150      97.23   38.54
  8,714      QNGH00000000   8,063,042     1,209,456,300   150      97.22   38.57
  10,938     QNGI00000000   8,083,052     1,212,457,800   150      97.38   38.29
  11,340     QNGJ00000000   8,081,886     1,212,282,900   150      97.32   38.26
  11,382     QNGK00000000   8,087,010     1,213,051,500   150      97.46   38.54
  12,645     QNGL00000000   8,067,526     1,210,128,900   150      97.14   38.92
  13,470     QNGM00000000   8,084,470     1,212,670,500   150      97.49   38.73
  13,484     QNGN00000000   8,079,076     1,211,861,400   150      97.40   38.69
  14,980     QNGO00000000   8,084,456     1,212,668,400   150      97.25   38.12
  15,224     QNGP00000000   8,048,514     1,207,277,100   150      97.36   37.96
  15,407     QNGQ00000000   8,070,056     1,210,508,400   150      97.17   38.31
  15,814     QNGR00000000   8,076,626     1,211,493,900   150      97.33   38.58
  17,838     QNGS00000000   8,051,770     1,207,765,500   150      96.89   38.51
  18,026     QNGT00000000   8,060,562     1,209,084,300   150      97.45   38.67
  19,663     QNGU00000000   8,081,042     1,212,156,300   150      97.50   38.41
  19,910     QNGV00000000   8,094,698     1,214,204,700   150      96.19   38.03
  23,903     QNGW00000000   8,061,246     1,209,186,900   150      96.02   37.90
  23,967     QNGX00000000   8,103,376     1,215,506,400   150      96.26   38.14
  24,393     QNGY00000000   8,109,796     1,216,469,400   150      96.00   38.20
  26,167     QNGZ00000000   8,097,538     1,214,630,700   150      96.20   38.21
  27,149     QNHA00000000   8,116,074     1,217,411,100   150      96.26   38.84
  27,451     QNHB00000000   8,111,306     1,216,695,900   150      96.16   38.37
  31,890     QNHC00000000   8,085,996     1,212,899,400   150      96.18   38.19
  32,142     QNHD00000000   8,069,526     1,210,428,900   150      96.02   37.82
  32,633     QNHE00000000   8,104,740     1,215,711,000   150      96.22   38.21
  33,710     QNHF00000000   8,104,866     1,215,729,900   150      96.22   38.01

**Abbreviation:** LZR-Efa, linezolid-resistant *Enterococcus faecalis*.

###### 

Characteristics of resistance genes

  Isolates   dfrE (n=26)   lsaA (n=26)   emeA (n=26)   fexA (n=23)   ANT(9) -Ia (n=12)   tetO (n=20)   dfrG (n=19)   ErmB (n=19)   tetK (n=18)   APH(3′)-IIIa (n=17)   AAC(6′)-Ie-APH(2″)-Ia (n=17)   cat (n=17)   satNA4 (n=16)   ErmA (n=18)   lnuB (n=12)   lsaE (n=12)   aad(6) (n=9)   tetS (n=2)   tetM (n=2)
  ---------- ------------- ------------- ------------- ------------- ------------------- ------------- ------------- ------------- ------------- --------------------- ------------------------------ ------------ --------------- ------------- ------------- ------------- -------------- ------------ ------------
  6,888      99.3%         98.8%         97.7%         98.9%         100.0%              NA            100.0%        NA            99.8%         100.0%                100.0%                         97.2%        99.4%           85.2%         100.0%        99.8%         100.0%         99.6%        95.7%
  8,714      100.0%        99.2%         97.7%         NA            NA                  NA            NA            NA            NA            NA                    NA                             NA           NA              NA            NA            NA            NA             NA           NA
  10,938     99.3%         98.8%         97.7%         98.9%         100.0%              95.6%         100.0%        100.0%        NA            100.0%                100.0%                         NA           98.9%           85.2%         100.0%        100.0%        100.0%         NA           NA
  11,340     100.0%        98.8%         97.7%         98.9%         NA                  95.3%         100.0%        100.0%        99.8%         100.0%                100.0%                         100.0%       99.4%           85.2%         NA            NA            100.0%         NA           NA
  11,382     100.0%        99.4%         97.7%         98.9%         NA                  95.5%         NA            100.0%        99.8%         NA                    NA                             97.2%        NA              85.2%         NA            NA            NA             NA           NA
  12,645     99.3%         98.2%         97.7%         NA            NA                  NA            NA            NA            NA            NA                    NA                             NA           NA              NA            NA            NA            NA             NA           NA
  13,470     99.3%         99.6%         97.7%         98.9%         NA                  95.5%         100.0%        100.0%        99.8%         100.0%                100.0%                         NA           99.4%           85.2%         NA            NA            100.0%         NA           NA
  13,484     100.0%        98.2%         97.7%         98.9%         NA                  90.9%         100.0%        100.0%        95.2%         NA                    99.7%                          97.2%        NA              85.2%         NA            NA            NA             NA           NA
  14,980     100.0%        99.4%         97.7%         98.9%         100.0%              95.5%         100.0%        100.0%        99.8%         100.0%                100.0%                         97.2%        99.4%           85.2%         100.0%        100.0%        NA             NA           NA
  15,224     99.3%         98.8%         97.7%         98.9%         NA                  95.6%         100.0%        100.0%        NA            NA                    NA                             100.0%       NA              85.2%         NA            NA            NA             NA           NA
  15,407     99.3%         98.8%         97.5%         NA            NA                  NA            NA            NA            NA            NA                    NA                             NA           NA              NA            NA            NA            NA             NA           NA
  15,814     99.3%         98.8%         97.7%         98.9%         100.0%              NA            100.0%        99.2%         99.8%         100.0%                100.0%                         97.2%        99.4%           85.2%         100.0%        100.0%        100.0%         99.6%        95.7%
  17,838     99.3%         99.6%         97.7%         98.9%         100.0%              95.5%         99.4%         100.0%        99.8%         100.0%                100.0%                         100.0%       99.4%           85.2%         100.0%        100.0%        100.0%         NA           NA
  18,026     100.0%        98.8%         97.7%         98.9%         NA                  95.5%         NA            99.6%         99.8%         100.0%                98.0%                          97.2%        99.4%           85.2%         NA            NA            NA             NA           NA
  19,663     99.3%         99.6%         97.7%         98.9%         100.0%              95.5%         100.0%        100.0%        99.8%         100.0%                100.0%                         100.0%       99.4%           85.2%         100.0%        99.8%         100.0%         NA           NA
  19,910     100.0%        99.0%         97.7%         98.9%         NA                  95.5%         100.0%        NA            99.8%         100.0%                NA                             NA           NA              85.2%         NA            NA            NA             NA           NA
  23,903     100.0%        99.4%         97.7%         98.9%         100.0%              95.5%         100.0%        100.0%        99.8%         100.0%                100.0%                         97.2%        99.4%           NA            100.0%        100.0%        NA             NA           NA
  23,967     100.0%        99.4%         97.7%         98.9%         100.0%              95.5%         100.0%        100.0%        99.8%         100.0%                100.0%                         97.2%        99.4%           NA            100.0%        100.0%        NA             NA           NA
  24,393     99.3%         99.6%         97.7%         98.9%         NA                  95.5%         NA            NA            99.8%         NA                    NA                             NA           NA              NA            NA            NA            NA             NA           NA
  26,167     99.3%         99.6%         97.7%         98.9%         NA                  95.5%         NA            100.0%        99.8%         100.0%                100.0%                         NA           99.4%           85.2%         NA            NA            100.0%         NA           NA
  27,149     100.0%        98.8%         97.7%         98.9%         100.0%              NA            100.0%        NA            NA            100.0%                100.0%                         100.0%       99.4%           85.2%         100.0%        100.0%        NA             NA           NA
  27,451     100.0%        99.4%         97.7%         98.9%         100.0%              95.5%         100.0%        100.0%        99.8%         100.0%                100.0%                         97.2%        99.4%           NA            100.0%        100.0%        NA             NA           NA
  31,890     100.0%        99.4%         97.7%         98.9%         100.0%              95.5%         100.0%        100.0%        99.8%         100.0%                100.0%                         97.2%        99.4%           NA            100.0%        100.0%        NA             NA           NA
  32,142     99.3%         98.8%         97.5%         98.9%         NA                  95.6%         100.0%        100.0%        NA            NA                    NA                             100.0%       NA              85.2%         NA            NA            NA             NA           NA
  32,633     100.0%        98.8%         97.7%         98.9%         100.0%              95.3%         100.0%        100.0%        99.8%         100.0%                100.0%                         NA           99.4%           85.2%         100.0%        100.0%        100.0%         NA           NA
  33,710     99.3%         98.8%         97.5%         98.9%         NA                  95.6%         100.0%        100.0%        NA            NA                    NA                             100.0%       NA              85.2%         NA            NA            NA             NA           NA

**Abbreviation:** NA, not available.

###### 

Characteristics of virulence genes

  Genes               6,888 (n=33)   8,714 (n=28)   10,938 (n=38)   11,340 (n=24)   11,382 (n=18)   12,645 (n=17)   13,470 (n=16)   13,484 (n=18)   14,980 (n=39)   15,407 (n=21)   15,224 (n=40)   15,814 (n=34)   17,838 (n=16)   18,026 (n=25)   19,663 (n=24)   19,910 (n=27)   23,903 (n=37)   23,967 (n=37)   24,393 (n=22)   26,167 (n=22)   27,149 (n=22)   27,451 (n=37)   31,890 (n=37)   32,142 (n=37)   32,633 (n=24)   33,710 (n=35)
  ------------------- -------------- -------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- --------------- ---------------
  ace (n=26)          \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  asa1 (n=18)         \+             −              \+              \+              −               −               \+              −               \+              −               \+              \+              \+              \+              \+              −               \+              \+              −               \+              −               \+              \+              \+              \+              \+
  bopD (n=26)         \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  bsh (n=1)           −              −              −               −               −               −               −               −               −               −               \+              −               −               −               −               −               −               −               −               −               −               −               −               −               −               −
  cpsA (n=26)         \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  cpsB (n=26)         \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  cpsC (n=18)         \+             \+             \+              \+              −               −               −               −               \+              \+              \+              \+              −               \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+              \+
  cpsD (n=18)         \+             \+             \+              \+              −               −               −               −               \+              \+              \+              \+              −               \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+              \+
  cpsE (n=18)         \+             \+             \+              \+              −               −               −               −               \+              \+              \+              \+              −               \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+              \+
  cpsF (n=17)         \+             \+             \+              \+              −               −               −               −               \+              \+              \+              \+              −               \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+              −
  cpsG (n=18)         \+             \+             \+              \+              −               −               −               −               \+              \+              \+              \+              −               \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+              \+
  cpsH (n=18)         \+             \+             \+              \+              −               −               −               −               \+              \+              \+              \+              −               \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+              \+
  cpsI (n=18)         \+             \+             \+              \+              −               −               −               −               \+              \+              \+              \+              −               \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+              \+
  cpsJ (n=18)         \+             \+             \+              \+              −               −               −               −               \+              \+              \+              \+              −               \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+              \+
  cpsK (n=18)         \+             \+             \+              \+              −               −               −               −               \+              \+              \+              \+              −               \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+              \+
  cylA (n=14)         \+             −              \+              −               −               −               −               −               \+              −               \+              \+              −               −               \+              −               \+              \+              \+              \+              −               \+              \+              \+              −               \+
  cylB (n=11)         \+             −              \+              −               −               −               −               −               \+              −               \+              \+              −               −               \+              −               \+              \+              −               −               −               \+              \+              \+              −               −
  cylI (n=14)         \+             −              \+              −               −               −               −               −               \+              −               \+              \+              −               −               \+              −               \+              \+              \+              \+              −               \+              \+              \+              −               \+
  cylL (n=10)         \+             −              \+              −               −               −               −               −               \+              −               \+              \+              −               −               \+              −               \+              \+              −               −               −               \+              \+              −               −               −
  cylM (n=13)         \+             −              \+              −               −               −               −               −               \+              −               \+              \+              \+              −               \+              −               \+              \+              −               −               −               \+              \+              \+              −               \+
  cylR1 (n=12)        \+             −              \+              −               −               −               −               −               \+              −               \+              \+              −               −               \+              −               \+              \+              −               −               −               \+              \+              \+              −               \+
  cylR2 (n=12)        \+             −              \+              −               −               −               −               −               \+              −               \+              \+              −               −               \+              −               \+              \+              −               −               −               \+              \+              \+              −               \+
  cylS (n=12)         \+             −              \+              −               −               −               −               −               \+              −               \+              \+              −               −               \+              −               \+              \+              −               −               −               \+              \+              \+              −               \+
  ebpA (n=25)         \+             \+             \+              \+              \+              −               \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  ebpB (n=26)         \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  ebpC (n=26)         \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  EF0149 (n=3)        −              −              −               −               −               −               −               −               \+              −               −               \+              −               \+              −               −               −               −               −               −               −               −               −               −               −               −
  EF0485 (n=14)       \+             −              \+              \+              −               −               −               −               \+              −               \+              \+              −               \+              \+                              \+              \+              −               −               −               \+              \+              \+              −               \+
  EF0818 (n=8)        −              \+             −               −               −               \+              \+              \+              −               \+              \+              −               −               −               −               −               −               −               \+              \+              −               −               −               −               −               −
  EF3023 (n=23)       \+             \+             \+              \+              \+              \+              \+              \+              \+              −               \+              \+              \+              \+              \+              \+              −               \+              \+              \+              \+              −               \+              \+              \+              \+
  efaA (n=26)         \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  esp (n=17)          \+             −              \+              −               \+              −               −               −               \+              −               \+              \+              \+              \+              \+              −               \+              \+              \+              −               −               \+              \+              \+              \+              \+
  fsrA (n=16)         −              \+             \+              −               \+              \+              −               \+              \+              −               \+              −               −               −               −               \+              \+              \+              \+              \+              −               \+              \+              \+              −               \+
  fsrB (n=17)         −              \+             \+              −               \+              \+              \+              \+              \+              −               \+              −               −               −               −               \+              \+              \+              \+              \+              −               \+              \+              \+              −               \+
  fsrC (n=17)         −              \+             \+              −               \+              \+              −               \+              \+              −               \+              −               −               −               −               \+              \+              \+              \+              \+              −               \+              \+              \+              \+              \+
  fss1 (n=26)         \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  fss2 (n=26)         \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
  gelE (n=17)         −              \+             \+              −               \+              \+              \+              \+              \+              −               \+              −               −               −               −               \+              \+              \+              \+              \+              −               \+              \+              \+              −               \+
  prgB/asc10 (n=17)   \+             \+             \+              \+              −               −               −               −               \+              −               \+              \+              \+              −               \+              \+              \+              −               \+              \+              \+              \+              −               \+              −               \+
  sprE (n=16)         −              \+             \+              −               \+              \+              −               \+              \+              −               \+              −               −               −               −               \+              \+              \+              \+              \+              −               \+              \+              \+              −               \+
  srtC (n=26)         \+             \+             \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+              \+
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![Minimum spanning tree of LZR-Efa. Solid line indicates one allele difference and dashed line indicates differences in two alleles.\
**Abbreviation:** LZR-Efa, linezolid-resistant *Enterococcus faecalis*.](idr-11-2397Fig1){#f1-idr-11-2397}

###### 

Clinical features of LZR-Efa

  Isolates   Sources   Ward          Age, y   Sex   Diagnosis                                   Prognosis     Region     Job       Year
  ---------- --------- ------------- -------- ----- ------------------------------------------- ------------- ---------- --------- ---------
  6,888      Urine     Outpatients   24       F     Urinary infection                           Improvement   Hangzhou   Worker    01/2012
  8,714      Blood     6B-17         62       F     Hepatolithiasis                             Improvement   Jinhua     Retired   01/2013
  10,938     Fester    5-1A          62       M     Metastatic carcinoma of bladder             Improvement   Huzhou     Worker    05/2013
  11,340     Ascites   6B-18         68       F     Hepatocholangiocarcinoma                    Improvement   Huzhou     Retired   06/2013
  11,382     Urine     Outpatients   41       F     Urinary infection                           Improvement   Hangzhou   Worker    06/2013
  12,654     Bile      6B-18         59       M     Hepatolithiasis                             Improvement   Huzhou     Farmer    08/2013
  13,470     Blood     3-4           67       M     Nephrostomy                                 Improvement   Jiaxing    Farmer    09/2013
  13,484     Fester    7-2           65       F     Mammary cancer                              Improvement   Hangzhou   Farmer    09/2013
  14,980     Urine     3-4           62       M     Prostatic cancer                            Improvement   Hangzhou   Retired   11/2013
  15,224     Urine     9-5           40       F     Nephrotic syndrome                          Improvement   Shaoxing   No        12/2013
  15,407     Bile      6B-18         51       F     Hepatolithiasis                             Improvement   Hangzhou   Worker    12/2013
  15,814     Urine     3-3           70       M     Prostatic hyperplasia                       Improvement   Wenzhou    Retired   01/2014
  17,838     Urine     10-5          64       F     Renal calculus                              improvement   Hangzhou   Retired   03/2014
  18,026     Urine     6B-7          32       M     IgA nephropathy                             Improvement   Hangzhou   Worker    04/2014
  19,663     Urine     Outpatients   23       F     Urinary infection                           Improvement   Hangzhou   Worker    06/2014
  19,910     Fester    3-2           18       M     Sacroiliac disease                          Improvement   Hangzhou   Student   07/2014
  23,903     Ascites   6B-12         60       F     Pancreatic cancer                           Improvement   Jiaxing    Retired   07/2014
  23,967     Bile      6A-4          63       M     Acute obstructive suppurative cholangitis   Improvement   Shaoxing   Worker    07/2014
  24,393     Urine     10-5          57       F     Ureteral calculus                           Improvement   Shaoxing   Farmer    08/2014
  26,167     Urine     5-2           37       F     Renal calculus                              Improvement   Hangzhou   Worker    11/2014
  27,149     Ascites   9-3           65       M     HIV                                         Died          Shaoxing   Farmer    12/2014
  27,451     Urine     Outpatients   46       F     Urinary infection                           Improvement   Hangzhou   Worker    01/2015
  31,890     Urine     10-1          69       M     Urethral stricture                          Improvement   Shaoxing   Retired   07/2015
  32,142     Urine     6A-8          64       F     Renal calculus                              Improvement   Jinhua     Retired   07/2015
  32,633     Ascites   7-2           68       F     Malignant tumor of abdominal wall           Improvement   Ningbo     Farmer    08/2015
  33,710     Ascites   5-1           41       M     Colonic tumor                               Improvement   Hangzhou   Worker    09/2015

**Abbreviations:** F, female; LZR-Efa, linezolid-resistant *Enterococcus faecalis*; M, male.

###### 

The antibiotic susceptibility and resistance mechanism of 26 LZR-Efa

  Isolates   OXA   CFZ   CXM    ERY    CLI    LVX    MXF    TC     TGC    AMK    FM    SXT              LZ   VAN   DAP   RIF    MLST                                             optrA                            23S rRNA
  ---------- ----- ----- ------ ------ ------ ------ ------ ------ ------ ------ ----- ---------------- ---- ----- ----- ------ ------------------------------------------------ -------------------------------- ------------------------------------------
  6,888      8     32    32     \>32   \>32   1      0.5    \>32   1      \>32   64    \>8/152          8    1     8     2      16                                               Ile86Arg, Glu238Lys, Pro463Thr   --
  8,714      8     16    8      1      8      2      1      1      0.25   \>32   32    0.25/4.75        8    1     8     \>4    674                                              NA                               Glu26Gln, Leu221Val, Glu260Lys
  10,938     8     32    32     \>32   \>32   \>32   32     \>32   1      \>32   32    \>8/152          8    1     4     2      16                                               --                               --
  11,340     8     32    \>32   \>32   \>32   \>32   32     \>32   0.5    \>32   64    \>8/152          16   1     4     1      476                                              --                               --
  11,382     8     32    16     \>32   \>32   \>32   16     \>32   1      \>32   64    \<0.015/0.25     8    1     2     1      856[a](#tfn2-idr-11-2397){ref-type="table-fn"}   Asp158Tyr, Pro463Thr             Leu156Phe, Arg172Gln
  12,654     8     16    16     2      32     2      1      1      0.5    \>32   32    2/38             8    2     2     \>4    857[a](#tfn2-idr-11-2397){ref-type="table-fn"}   NA                               Val30Leu, Gly57Ser, Pro236Ser, Ile269Val
  13,470     16    32    \>32   \>32   \>32   \>32   16     \>32   0.5    \>32   64    \>8/152          8    1     4     1      480                                              Asp158Tyr, Pro463Thr             Thr95Ile, Glu260Lys
  13,484     16    32    \>32   \>32   \>32   4      1      \>32   1      \>32   32    \>8/152          8    2     8     2      21                                               Asp158Tyr, Pro463Thr             Val30Leu, Gly57Ser, Pro236Ser, Ile269Val
  14,980     16    32    \>32   \>32   \>32   \>32   16     \>32   0.5    \>32   64    \>8/152          8    1     4     0.5    585                                              --                               Arg172Gln, Pro236Ser
  15,224     8     16    \>32   \>32   \>32   32     16     32     0.5    \>32   32    \>8/152          8    1     2     1      16                                               Asp158Tyr, Pro463Thr             --
  15,407     8     16    32     \>32   \>32   1      0.25   1      0.25   \>32   64    0.25/4.75        8    0.5   4     2      479                                              NA                               Pro81Ser, Ala177Ser
  15,814     8     32    16     \>32   \>32   1      0.5    \>32   1      \>32   32    \>8/152          8    1     4     1      16                                               Ile86Arg, Glu238Lys, Pro463Thr   --
  17,838     16    32    \>32   \>32   \>32   32     8      \>32   0.5    \>32   8     0.25/4.75        8    1     4     2      480                                              --                               Thr95Ile, Glu260Lys
  18,026     16    32    \>32   \>32   \>32   32     16     \>32   0.5    \>32   32    0.0315/0.59375   8    1     4     4      476                                              --                               --
  19,663     16    32    \>32   \>32   \>32   32     8      \>32   0.5    \>32   64    \>8/152          8    1     2     2      480                                              Asp158Tyr, Pro463Thr             Thr95Ile, Glu260Lys
  19,910     16    32    \>32   \>32   \>32   16     4      \>32   0.5    \>32   32    \>8/152          8    2     4     \>4    116                                              Asp158Tyr, Pro463Thr             Arg172Gln
  23,903     16    32    \>32   \>32   \>32   \>32   16     \>32   0.5    \>32   64    \>8/152          8    1     4     0.5    585                                              Pro463Thr, Ile604Met             Arg172Gln, Pro236Ser
  23,967     16    32    \>32   \>32   \>32   \>32   16     \>32   0.5    \>32   64    \>8/152          8    1     4     0.5    585                                              Pro463Thr, Ile604Met             Arg172Gln, Pro236Ser
  24,393     8     16    16     2      32     1      0.5    \>32   0.5    \>32   32    0.0625/1.1875    16   1     4     4      81                                               Asp158Tyr, Pro463Thr             Glu154Gln, Pro236Ser, Ile269Val
  26,167     8     16    16     \>32   \>32   1      0.5    \>32   1      \>32   64    \<0.015/0.25     8    1     2     2      619                                              Asp158Tyr, Pro463Thr             Glu154Gln, Pro236Ser, Ile269Val
  27,149     8     32    32     \>32   \>32   \>32   32     1      0.5    \>32   32    \>8/152          8    1     4     2      858[a](#tfn2-idr-11-2397){ref-type="table-fn"}   Asp158Tyr, Pro463Thr             --
  27,451     16    32    \>32   \>32   \>32   \>32   16     \>32   0.5    \>32   32    \>8/152          8    1     4     0.25   585                                              --                               Arg172Gln, Pro236Ser
  31,890     16    32    \>32   \>32   \>32   \>32   32     \>32   0.5    \>32   32    \>8/152          8    1     8     4      585                                              Pro463Thr, Ile604Met             Arg172Gln, Pro236Ser
  32,142     8     32    16     \>32   \>32   \>32   32     \>32   0.5    \>32   128   \>8/152          8    1     4     1      16                                               Asp158Tyr, Pro463Thr             --
  32,633     16    32    32     \>32   \>32   \>32   32     \>32   0.5    \>32   32    \>8/152          8    1     4     1      476                                              Asp158Tyr, Pro463Thr             --
  33,710     8     32    32     \>32   \>32   \>32   32     \>32   0.5    \>32   32    \>8/152          8    1     4     1      16                                               Asp158Tyr, Pro463Thr             --

**Note:**

New ST types.

**Abbreviations:** AMK, amikacin; CFZ, cefazolin; CLI, clindamycin; CXM, cefuroxime; DAP, daptomycin; ERY, erythromycin; FM, fosfomycin; LVX, levofloxacin; LZ, linezolid; LZR-Efa, linezolid-resistant *Enterococcus faecalis;* MLST, multilocus sequence typing; MXF, moxifloxacin; NA, not available; OXA, oxacillin; RIF, rifampin; SXT, trimethoprim-sulfamethoxazole; TC, tetracycline; TGC, tigecycline; VAN, vancomycin.

###### 

Risk factors for patients with LZR-Efa at univariate analysis

                        LZR-Efa (n=20)   LZS-Efa (n=40)   *P*-value
  --------------------- ---------------- ---------------- -----------
  CP                    4 (20%)          7 (17.5%)        0.813
  CEP                   5 (25%)          14 (35%)         0.432
  BL/BLI                7 (35%)          8 (20%)          0.206
  CAR                   7 (35%)          3 (7.5%)         0.007
  NIT                   2 (10%)          6 (15%)          0.591
  QUI                   6 (30%)          6 (15%)          0.171
  AMI                   2 (10%)          4 (10%)          1
  GLY                   2 (10%)          1 (2.5%)         0.209
  FM                    1 (5%)           0                0.154
  SXT                   0                2 (5%)           0.309
  Bowel preparation     7 (35%)          15 (37.5%)       0.85
  Operation             11 (55%)         20 (50%)         0.715
  Indwelling catheter   9 (45%)          20 (50%)         0.715
  ICU                   2 (10%)          1 (2.5%)         0.209

**Abbreviations:** AMI, aminoglycoside; BL/BLI, β-lactams and β-lactamase inhibitors; CAR, carbapenems; CEP cephalosporin; CP, cephamicins; FM, fosfomycin; GLY, glycopeptide; ICU, intensive care unit; LZR-Efa, linezolid-resistant E. faecalis; LZS-Efa, linezolid-sensitive E. faecalis; NIT, nitromidazoles; QUI, quinolones; SXT, trimethoprimsulfamethoxazole.

[^1]: These authors contributed equally to this work
